Assessment of performance characteristics of COVID-19 ICD-10-CM diagnosis code U07.1 using SARS-CoV-2 nucleic acid amplification test results

Author:

Moll KeranORCID,Hobbi Shayan,Zhou Cindy Ke,Fingar Kathryn,Burrell Timothy,Hernandez-Medina Veronica,Obidi Joyce,Alawar Nader,Anderson Steven A.,Wong Hui-Lee,Shoaibi Azadeh

Abstract

The Food and Drug Administration’s Biologics Effectiveness and Safety Initiative conducts active surveillance to protect public health during the coronavirus disease 2019 (COVID-19) pandemic. This study evaluated performance of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code U07.1 in identifying COVID-19 cases in claims compared with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification test results in linked electronic health records (EHRs). Care episodes in three populations were defined using COVID-19-related diagnoses (population 1), SARS-CoV-2 nucleic acid amplification test procedures (population 2), and all-cause hospitalizations (population 3) in two linked claims-EHR databases: IBM® MarketScan® Explorys® Claims-EMR Data Set (commercial) and OneFlorida Data Trust linked Medicaid-EHR. Positive and negative predictive values were calculated. Respectively, populations 1, 2, and 3 included 26,686, 26,095, and 2,564 episodes (commercial) and 29,117, 23,412, and 9,629 episodes (Florida Medicaid). The positive predictive value was >80% and the negative predictive value was >95% in each population, with the highest positive predictive value in population 3 (commercial: 91.9%; Medicaid: 93.1%). Findings did not vary substantially by patient age. Positive predictive values in populations 1 and 2 fluctuated during April–June 2020. They then stabilized in the commercial but not the Medicaid population. Negative predictive values were consistent over time in all populations and databases. Our findings indicate that U07.1 has high performance in identifying COVID-19 cases and noncases in claims databases. Performance may vary across populations and periods.

Funder

Food and Drug Administration

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference13 articles.

1. World Health Organization. Emergency Use ICD Codes for COVID-19 Disease Outbreak [cited 2022 Jan 1]. Available from: https://www.who.int/classifications/icd/covid19/en/#:~:text=The%20COVID%2D19%20disease%20outbreak,%2D10%20code%20of%20’U07

2. Centers for Disease Control and Prevention. ICD-10-CM Official Coding and Reporting Guidelines: April 1, 2020 through September 30, 2020 [cited 2022 June 23]. Available from: https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf

3. Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations;S Kadri;JAMA,2020

4. Centers for Disease Control and Prevention. COVIDView Summary ending January 2, 2021 [updated 2021 Jan 8

5. cited 2022 June 23]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/01082021.html

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3